PT-141

What is PT-141?

PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin receptors in the central nervous system. It is a metabolite of an earlier compound, Melanotan II, but was developed specifically for its effects on sexual desire rather than skin pigmentation.

What sets PT-141 apart from more familiar treatments is where it works. PDE5 inhibitors like sildenafil (Viagra) and tadalafil (Cialis) act on the vascular system to improve blood flow. PT-141 acts upstream, in the brain, on the pathways that generate desire and arousal in the first place. Under the brand name Vyleesi it is FDA-approved for one specific indication; its use in men and other contexts is off-label and, in the United States, typically pharmacy-compounded.

How PT-141 works

PT-141 is an agonist at melanocortin receptors, with its sexual effects attributed mainly to activation of the MC4 receptor in the hypothalamus and related regions of the central nervous system. Rather than dilating blood vessels, it modulates the neural circuitry — including dopaminergic signaling — that governs sexual motivation and arousal.

This central mechanism is why PT-141 is described as working on desire itself, not just the physical machinery of arousal. It also explains why the drug is dosed episodically ahead of anticipated activity rather than taken to produce an immediate erectile response the way a vascular agent does [1][3].

What PT-141 is used for

What the evidence shows

PT-141's strongest evidence is in premenopausal women. Two large randomized, placebo-controlled phase 3 trials (the RECONNECT studies) supported its FDA approval, showing statistically significant improvements in sexual desire and reductions in the distress associated with low desire versus placebo [2].

The effect size is real but modest, and the trials measured changes on validated desire and distress scales rather than a dramatic transformation. We share that honestly: PT-141 is a meaningful option for the right patient, not a guarantee, and the benefit is best judged against your own baseline over a fair trial.

Evidence for off-label uses — including in men — is thinner, drawn largely from earlier-phase and mechanistic studies rather than the large confirmatory trials that underpin the Vyleesi indication [1][3]. Where the data are weaker, we say so.

Dosing & administration context

As Vyleesi, PT-141 is given by subcutaneous injection using a prefilled autoinjector, taken on an as-needed basis at least 45 minutes before anticipated sexual activity. The labeled schedule limits how frequently it can be used — no more than one dose in 24 hours and a capped number of doses per month — because more frequent use raises side-effect and blood-pressure concerns [1].

Compounded PT-141 for off-label use may differ in concentration and route, which is exactly why dose, timing, and frequency belong to the prescribing physician rather than to a self-dosing guide. Product obtained without a prescription carries no assurance of identity, purity, or sterility.

PT-141 is FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women. Use in men or other contexts is off-label and, in the U.S., pharmacy-compounded. This page is clinical context, not a dosing guide or a substitute for medical advice.

Safety & side effects

The most common issue with PT-141 is nausea, which is frequent, can be significant, and is the leading reason patients stop the drug. Flushing, headache, and injection-site reactions are also common. PT-141 causes a transient rise in blood pressure and a fall in heart rate for several hours after each dose [1].

Because of those cardiovascular effects, PT-141 is not appropriate for people with uncontrolled hypertension or known cardiovascular disease, and we screen for these before prescribing. Repeated use can also cause focal darkening of the skin (hyperpigmentation), which may not fully resolve. We monitor tolerability and blood pressure throughout treatment.

How Strong Health prescribes PT-141

At Strong Health, PT-141 is prescribed only after a physician evaluation that includes your sexual-health history, a blood-pressure and cardiovascular review, and screening for other causes of low desire. For the FDA-approved indication we can prescribe Vyleesi directly; for off-label use we work exclusively through licensed 503A or 503B compounding pharmacies under physician orders.

We set expectations honestly, start with the lowest reasonable dosing, and review tolerability — particularly nausea and blood pressure — before continuing. PT-141 is treated as one part of a broader sexual-health assessment, not a standalone fix, and your physician adjusts or stops treatment based on how you respond.

Available in person at our Miami (Brickell) clinic and via telehealth across our service areas.

Frequently asked questions